Gastroesophageal reflux disease is a condition which results from the recurrent backflow of gastric contents into the esophagus and adjacent structures causing troublesome symptoms and/or tissue injury.
It is produced by various mechanisms such as frequent occurrence of transient relaxation of the lower esophageal sphincter or pressure abnormalities in the lower esophageal sphincter (which can be caused by hormonal and neural mediators, food, drugs and patient lifestyle).
Typical symptoms are acid regurgitation and heartburn.
Acid regurgitation is the perception of flow of refluxed gastric contents into the mouth or hypopharynx.
Heartburn is the burning sensation in the retrosternal region.

Gastroesophageal Reflux Disease References

  1. Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2004 Apr;19(4):357-367. PMID: 15012771
  2. DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005 Jan;100(1):190-200. PMID: 15654800
  3. Dent J, Jones R, Kahrilas P, et al. Management of gastro-esophageal reflux disease in general practice. BMJ. 2001 Feb;322(7282):344-347. PMID: 11159660
  4. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005 Jan;19(1):15-35. PMID: 15685294
  5. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-328. doi: 10.1038/ajg.2012.444. Accessed 18 Jul 2013. PMID: 23419381
  6. Vakil N, van Zanten SV, Kahrilas P, et al; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-1920. PMID: 16928254
  7. MedWorm
  8. MedWorm
  9. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel Veterans Health Administration Department of Veterans Affairs. VHA/DoD clinical practice guideline for the management of adults with gastroesophageal reflux disease in primary care practice. Mar 2003.
  10. New Zealand Guidelines Group. Management of dyspepsia and heartburn: evidence-based practice guideline. Jun 2004.
  11. MedWorm
  12. Poh J. Restrictions on the use of metoclopramide-containing products. Drug safety information no. 57. Health Sciences Authority (HSA). 23 Jul 2015. Accessed 24 Jul 2015.
  13. Sollano JD, Romano RP, Ibanez-Guzman L, et al. Clinical practice guidelines on the diagnosis and treatment of gastroesophageal reflux disease (GERD). Philippine Journal of Internal Medicine. 2015 Jul-Sep;53(3):1-17. Accessed 02 Oct 2015
  14. Hunt R, Armstrong D, Katelaris P, et al. GERD. Global perspective on gastroesophageal reflux disease. World Gastroenterology Organisation (WGO). Oct 2015. Accessed 06 May 2016.
  15. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016 Aug;51(8):751-767. doi: 10.1007/s00535-016-1227-8. PMID: 27325300
  16. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-767. doi: 10.1111/j.1365-2036.2012.05011.x. PMID: 22356640
  17. Wiśniowska B, Tylutki Z, Wyszogrodzka G, et al. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016 Mar 10;17:12. doi: 10.1186/s40360-016-0053-1. PMID: 26960809
  18. Wolfe MM. Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders. UpToDate. 02 Jun 2016. Accessed 27 Dec 2016.
  19. Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut. 2016 Sep;65(9):1402-1415. doi: 10.1136/gutjnl-2016-311715. PMID: 27261337
  20. Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017 Jul;51(6):467-478. doi: 10.1097/MCG.0000000000000854. PMID: 28591069
  21. Koop H. Medical therapy of gastroesophageal reflux disease beyond proton pump inhibitors: where are we heading?. Visc Med. 2018 Apr;34(2):110-115. doi: 10.1159/000486692. PMID: 29888239
  22. Niikura R, Yamada A, Hirata Y, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018 Sep;57(17):2443-2450. doi: 10.2169/internalmedicine.0492-17. PMID: 29607951
  23. Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related dieases. J Neurogastroenterol Motil. 2018 Jul;24(3):334-344. doi: 10.1056/jnm18029. PMID: 29739175
  24. Shinozaki S, Osawa H, Hayashi Y, et al. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2017 Sep;7(3):231-235. doi: 10.3892/br.2017.947. PMID: 28894571
  25. Vakil NB. Antiulcer medications: mechanism of action, pharmacology, and side effects. UpToDate. 22 May 2018. Accessed 13 Dec 2018.
  26. MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract. 2018 Jun;7:41-52. doi: 10.2147/IPRP.S142932. PMID: 29892570
  27. Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. Gut Liver. 2018 Jan;12(1):7-16. doi: 10.5009/gnl16615. PMID: 28427116
  28. Hojo M, Nagahara A, Hahm KB, et al. Management of gastroesophageal reflux disease in Asian countries: Results of a questionnaire survey. Digestion. 2020;101(1):66-79. doi: 10.1159/000504749. PMID: 31801133
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 3 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.